{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:08:03Z","timestamp":1788984483811,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.eururo.2018.09.005","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T19:36:43Z","timestamp":1538163403000},"page":"63-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":132,"title":["Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Gu\u00e9rin or Institutional Standard in Patients with Recurrence of Non\u2013muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Gu\u00e9rin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial"],"prefix":"10.1016","volume":"75","author":[{"given":"Wei Shen","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anesh","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Devall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence S.","family":"Loubi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Feneley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Cresswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Mostafid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Madaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Sangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.R. Leyshon","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibendra N.","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda J.","family":"Billingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2018.09.005_bib0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0135","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0140","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.6004\/jnccn.2016.0131","article-title":"NCCN Guidelines insights: bladder cancer, version 2.2016","volume":"14","author":"Clark","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2018.09.005_bib0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2016.05.002","article-title":"Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia","volume":"47","author":"Tan","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2018.09.005_bib0150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.euf.2016.06.002","article-title":"In-depth critical analysis of complications following robot-assisted radical cystectomy with intracorporeal urinary diversion","volume":"3","author":"Tan","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2018.09.005_bib0155","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.juro.2010.06.007","article-title":"Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series","volume":"184","author":"Stimson","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0160","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0022-5347(17)39546-0","article-title":"Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor","volume":"144","author":"Coplen","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0165","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.juro.2007.05.024","article-title":"A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder","volume":"178","author":"Harland","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0170","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.ju.0000146274.85012.e1","article-title":"Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study","volume":"173","author":"van der Heijden","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0175","doi-asserted-by":"crossref","first-page":"12083","DOI":"10.1038\/srep12083","article-title":"Radiofrequency treatment alters cancer cell phenotype","volume":"5","author":"Ware","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2018.09.005_bib0180","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin c versus bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate-and high-risk non\u2013muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0185","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","article-title":"The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review","volume":"60","author":"Lammers","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0190","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000471701","article-title":"Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study","volume":"20","author":"Rigatti","year":"1991","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0195","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-5347(01)67613-4","article-title":"A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment","volume":"153","author":"Colombo","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eururo.2004.01.019","article-title":"Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder","volume":"46","author":"van der Heijden","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0205","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.eururo.2018.09.005_bib0210","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00345-008-0350-4","article-title":"Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer","volume":"27","author":"Park","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0215","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ng1061","article-title":"Identifying distinct classes of bladder carcinoma using microarrays","volume":"33","author":"Dyrskj\u00f8t","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2018.09.005_bib0220","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","article-title":"Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)","volume":"107","author":"Colombo","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.09.005_bib0225","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","article-title":"Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma","volume":"21","author":"Colombo","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0230","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0235","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.09.005_bib0240","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0245","first-page":"e700","volume":"189","author":"L\u00fcdecke","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.09.005_bib0250","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818306559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818306559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T10:09:21Z","timestamp":1567159761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283818306559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0302283818306559"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2018.09.005","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Gu\u00e9rin or Institutional Standard in Patients with Recurrence of Non\u2013muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Gu\u00e9rin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}